

## Special Issue

# New Insights into Cancer Vaccines and Immunotherapy

### Message from the Guest Editor

Immune-based therapies are powerful tools in the fight against cancer. The similarities in canine and human cancer genetics and therapeutic responses have promoted comparative oncology as an important research area for developing better treatments for animal and human disease. New technical developments in genomics and proteomics paired with the fervent climate of modern data science bioinformatics have made comparative oncology a cutting-edge field when it comes to understanding genetic and epigenetic causes of cancer. This Special Issue is focused on recent advancements in the discovery of immune-based therapies and how comparative oncology will lead to a better understanding of how the immune system can be harnessed for personalized and preventative medicines.

---

### Guest Editor

Prof. Dr. Ted Hupp

International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland and the University of Edinburgh, Cancer Research Centre, Edinburgh O131, UK

---

### Deadline for manuscript submissions

closed (31 January 2020)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/28375](https://mdpi.com/si/28375)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)